Synageva BioPharma (GEVA)

[mskatiescarletohara]

Hi there RSox....no I have not listened to the CC, however, I believe the stock will at least triple again in the next two years if their new fusion inhibitors show promise in the clinic. I'm eager to learn more about the Roche/TRMS development strategy on these new compounds. I think institutions own roughly 90% of TRMS, paper is scarce on this stock.

TRMS ALWAYS hosts quarterly CCs whether the news is good or bad!

katie...